Cancer research
Researchers at Hebei General Hospital in Hebei, People's Republic of China, have made significant discoveries about the role of ammonia-induced cell death (AID) in gastric adenocarcinoma (STAD). Their study, published in Cancer Cell International, has provided new insights into the mechanisms of AID and its impact on immune
Cancer
Researchers in Hefei, People's Republic of China, have identified a six-gene risk signature associated with the prognosis and therapeutic response in gastric cancer patients. Using a dataset from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), the study found that the signature can predict the
Cancer
Research from Kangbuk Samsung Hospital in South Korea has developed a deep learning-based classifier to detect Epstein-Barr virus (EBV) positivity in gastric cancer biopsy and resection specimens. The system, called EBV-TRACER, uses stain normalization to improve accuracy and has been validated on a dataset of 2684 gastric specimens. The results
Cancer
Research at Chiba University, Japan, has established a connection between Epstein-Barr Virus (EBV) and gastric cancer through the suppression of apoptosis. The study, published in The Journal of Pathology, found that EBV-positive gastric cancers (GCs) exhibit unique carcinogenic pathways that evade apoptosis in the absence of TP53 mutation. The research
Cancer
Recent research conducted at Chengdu Medical College in Sichuan, People's Republic of China, has shed light on the pivotal epigenetic driver of gastric cancer (GC) pathogenesis. The study, published in Cell Biology and Toxicology, highlights the role of N-6-methyladenosine (m(6)A) modification, orchestrated by methyltransferase-like 3 (METTL3)
Cancer
Research has identified that gastric cancer patients with poor preoperative nutritional status have significantly reduced overall survival rates. The study, conducted at Fujian Medical University, analyzed data from 19,285 patients from 27 global cohorts between 2016 and 2023. The Prognostic Nutritional Index (PNI) and Nutritional Risk Screening 2002 (NRS-2002)
Cancer research
Researchers at the University of Genoa in Italy have made significant contributions to the understanding of PD-L1 expression in gastric cancer. A new report presents findings from a multicentric, real-world retrospective study that analyzed data from 28 Italian pathology centers, covering 1936 cases of esophageal, esophagogastric junction, and gastric carcinoma
Cancer
Researchers at the University Hospital Larissa in Greece have made significant progress in understanding the application of CRISPR/Cas9 gene editing technology in gastric cancer research. The current study highlights the potential of CRISPR/Cas9 in identifying oncogenes and tumor suppressors, modeling tumor microenvironment interactions, and developing gene-based therapies for
Cancer
Researchers at Hiroshima University have published a new study on the prognosis and treatment of gastric cancer, specifically in cases where peritoneal lavage cytology is positive (CY1). The study, published in the World Journal of Gastrointestinal Oncology, analyzed data from 13 institutions over a 5-year period (2015-2019) and included 82
Cancer
The International Gastric Cancer Educational Symposium for Patients, co-hosted by Debbie's Dream Foundation: Curing Stomach Cancer (DDF) and the Japanese Foundation for Cancer Research, aims to strengthen global collaboration in research, advocacy, and patient care for gastric cancer. The symposium, taking place on November 15, 2025, will bring
Cancer
Recent research from Guilan University of Medical Sciences in Rasht, Iran, has made significant strides in understanding gastric cancer through the application of bioinformatics. Gastric cancer, one of the most prevalent malignancies globally, has a high mortality rate due to its molecular heterogeneity, late-stage diagnosis, and limited efficacy of existing
Cancer
Henlius has achieved a significant breakthrough in the treatment of gastric cancer with the success of its phase 3 clinical study, ASTRUM-006, which met its primary endpoint of Event-Free Survival (EFS) for patients treated with the company's innovative anti-PD-1 monoclonal antibody, HANSIZHUANG, in combination with chemotherapy. This marks
